CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimo

Posted Apr 27 by Two Blokes

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohor

Source: Two Blokes Trading

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigati

Posted Apr 27 by Two Blokes

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing

Source: Two Blokes Trading

China has exempted some U.S. imports that the country would struggle to immediately source from elsewhere from its retaliatory t

Posted Apr 27 by Two Blokes

Beijing has been canvassing companies and waiving duties on American goods in sectors where it lacks alternati

Source: Two Blokes Trading

The Best REIT Stocks to Invest $1,000 in Right Now

Posted Apr 27 by Two Blokes

Real estate is the oldest asset class in the book -- it's timeless.

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients

Posted Apr 27 by Two Blokes

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical ben

Posted Apr 27 by Two Blokes

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-ri

Posted Apr 27 by Two Blokes

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-ri

Posted Apr 27 by Two Blokes

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu

Source: Two Blokes Trading

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo\u2122 robotic-assisted surger

Posted Apr 27 by Two Blokes

Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted

Source: Two Blokes Trading

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Re

Posted Apr 27 by Two Blokes

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical com

Source: Two Blokes Trading

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimo

Posted Apr 27 by Two Blokes

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohor

Source: Two Blokes Trading

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigati

Posted Apr 27 by Two Blokes

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing

Source: Two Blokes Trading